T细胞表面含有特异性的T细胞受体（T cell receptors，TCR），能够识别不同的肿瘤抗原，从而实现对癌变细胞的杀伤和清除。TCR工程化T细胞（TCR-engineered T cells，TCR-T）治疗即是通过钓取针对肿瘤细胞的特异性TCR，并应用基因工程技术改造T细胞，输注体内后可达到治疗肿瘤的目的。尽管TCR-T治疗取得一定成果，但是还存在治疗毒性、T细胞浸润有限、抗原特异性不佳等问题，需要不断优化TCR-T治疗的安全性和有效性。因此，本文阐述了目前国内外关于实体肿瘤TCR-T治疗的研究现状以及存在的问题与对策。

T cell receptors (TCR) are specifically expressed on T cell surface, which can recognize different tumor antigens to kill and scavenge cancerous cells. TCR-engineered T cells (TCR-T) therapy is to harbor TCR specific to tumor cells and modify the T cells with genetic engineering techniques to achieve the purpose of treating tumors after transfusion. Despite some achievements in TCR-T therapy,there are still some problems, such as treatment toxicity, limited T cell infiltration and antigen-specific deficiency and so on. So, the safety and effectiveness of TCR-T therapy need to be constantly optimized. Therefore，this paper summarizes the research status of TCR-T therapy for solid tumors in domestic and overseas, as well as the existing problems and countermeasures.

福建省科技创新联合资金资助项目（No.2018Y9108）